OM:SPEC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has SpectraCure's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SPEC has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

7.1%

SPEC

-4.8%

SE Medical Equipment

-4.6%

SE Market


1 Year Return

-35.7%

SPEC

12.3%

SE Medical Equipment

9.8%

SE Market

Return vs Industry: SPEC underperformed the Swedish Medical Equipment industry which returned 11.7% over the past year.

Return vs Market: SPEC underperformed the Swedish Market which returned 9.5% over the past year.


Shareholder returns

SPECIndustryMarket
7 Day7.1%-4.8%-4.6%
30 Day-6.3%-3.8%-1.3%
90 Day21.3%-0.1%2.3%
1 Year-35.7%-35.7%14.0%12.3%11.7%9.8%
3 Year120.5%120.5%60.6%41.9%26.1%12.6%
5 Year1,169.1%957.6%65.0%36.8%52.1%22.6%

Price Volatility Vs. Market

How volatile is SpectraCure's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is SpectraCure undervalued compared to its fair value and its price relative to the market?

7.78x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SPEC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SPEC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SPEC is unprofitable, so we can't compare its PE Ratio to the SE Medical Equipment industry average.

PE vs Market: SPEC is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SPEC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SPEC is overvalued based on its PB Ratio (7.7x) compared to the SE Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is SpectraCure forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SpectraCure has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has SpectraCure performed over the past 5 years?

-23.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SPEC is currently unprofitable.

Growing Profit Margin: SPEC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SPEC is unprofitable, and losses have increased over the past 5 years at a rate of 23.2% per year.

Accelerating Growth: Unable to compare SPEC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SPEC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.4%).


Return on Equity

High ROE: SPEC has a negative Return on Equity (-7.5%), as it is currently unprofitable.


Next Steps

Financial Health

How is SpectraCure's financial position?


Financial Position Analysis

Short Term Liabilities: SPEC's short term assets (SEK184.0M) exceed its short term liabilities (SEK23.8M).

Long Term Liabilities: SPEC's short term assets (SEK184.0M) exceed its long term liabilities (SEK4.2M).


Debt to Equity History and Analysis

Debt Level: SPEC is debt free.

Reducing Debt: SPEC has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SPEC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SPEC has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 27.5% each year.


Next Steps

Dividend

What is SpectraCure current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SPEC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SPEC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SPEC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SPEC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SPEC's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Masoud Khayyami (57 yo)

no data

Tenure

Dr. Masoud Khayyami, Ph.D. is a Founder and serves as Manager at MK Capital AB. He serves as Chairman of the Board of Lumito AB (publ). He serves as the Chief Executive Officer at SpectraCure AB. He is a f ...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.1%.


Top Shareholders

Company Information

SpectraCure AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SpectraCure AB (publ)
  • Ticker: SPEC
  • Exchange: OM
  • Founded: 2003
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr1.591b
  • Shares outstanding: 87.47m
  • Website: https://www.spectracure.com

Number of Employees


Location

  • SpectraCure AB (publ)
  • Gasverksgatan 1
  • Lund
  • Skåne County
  • 222 29
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SPECOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKJul 2015
2OKDB (Deutsche Boerse AG)YesShare CapitalDEEURJul 2015

Biography

SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system, which is in Phase II clin ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/28 22:28
End of Day Share Price2020/10/28 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.